[go: up one dir, main page]

GT200300212A - Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia - Google Patents

Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia

Info

Publication number
GT200300212A
GT200300212A GT200300212A GT200300212A GT200300212A GT 200300212 A GT200300212 A GT 200300212A GT 200300212 A GT200300212 A GT 200300212A GT 200300212 A GT200300212 A GT 200300212A GT 200300212 A GT200300212 A GT 200300212A
Authority
GT
Guatemala
Prior art keywords
peperazinas
heterociclicas
chichophrenia
replaced
treatment
Prior art date
Application number
GT200300212A
Other languages
English (en)
Inventor
Jamie Marie Davis
Tracy Fay Gregory
Michael Anthony Walters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300212A publication Critical patent/GT200300212A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL I EN LA QUE Q,AR,A,R2,R3, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS PRESENTAN ACTIVIDAD COMO ANTAGONISTAS DE RECEPTORES DE DOPAMINA D2 Y RECEPTORES DE SEROTONINA 2A, PRINCIPALMENTE, POR LO QUE SON DE UTILIDAD EN TRASTORNOS DEL SNC TALES COMO LA ESQUIZOFRENIA.
GT200300212A 2002-09-26 2003-09-24 Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia GT200300212A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41383902P 2002-09-26 2002-09-26

Publications (1)

Publication Number Publication Date
GT200300212A true GT200300212A (es) 2004-05-25

Family

ID=32043299

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300212A GT200300212A (es) 2002-09-26 2003-09-24 Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia

Country Status (14)

Country Link
US (1) US20040067960A1 (es)
EP (1) EP1546145A1 (es)
JP (1) JP2006503846A (es)
AR (1) AR041376A1 (es)
AU (1) AU2003260882A1 (es)
BR (1) BR0314796A (es)
CA (1) CA2500115A1 (es)
GT (1) GT200300212A (es)
MX (1) MXPA05002003A (es)
PA (1) PA8583801A1 (es)
PE (1) PE20050133A1 (es)
TW (1) TW200413363A (es)
UY (1) UY27998A1 (es)
WO (1) WO2004029048A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562919A1 (en) * 2002-11-08 2005-08-17 Warner-Lambert Company LLC Phenylalkyl and pyridylalkyl piperazine derivatives
EP1697334A1 (en) * 2003-12-08 2006-09-06 Warner-Lambert Company LLC Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
US20090076028A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched itraconazole
US20090076027A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20090082363A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched posaconazole
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
JP5714152B2 (ja) * 2014-03-26 2015-05-07 江蘇恒誼薬業有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
US10160778B2 (en) * 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN115521302B (zh) * 2022-09-20 2025-03-21 徐州医科大学 一种四氢（异）喹啉或吲哚啉类衍生物、组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6242450B1 (en) * 1998-07-27 2001-06-05 Eli Lilly And Company 5-HT1F antagonists
ES2244438T3 (es) * 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
CA2426706A1 (en) * 2000-10-26 2002-05-02 Smithkline Beecham P.L.C. Benzoxazinone derivatives, their preparation and use

Also Published As

Publication number Publication date
US20040067960A1 (en) 2004-04-08
UY27998A1 (es) 2004-04-30
TW200413363A (en) 2004-08-01
JP2006503846A (ja) 2006-02-02
BR0314796A (pt) 2005-07-26
PE20050133A1 (es) 2005-03-22
WO2004029048A1 (en) 2004-04-08
EP1546145A1 (en) 2005-06-29
PA8583801A1 (es) 2004-05-07
MXPA05002003A (es) 2005-08-03
CA2500115A1 (en) 2004-04-08
AR041376A1 (es) 2005-05-11
AU2003260882A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
GT200800033A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
DOP2009000126A (es) Antagonistas de receptor de orexina de diazepan sustituído
GT200300212A (es) Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia
GT200200073A (es) Derivados de dihidro-benzo (b) (1,4) diazepin-2-ona
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
GT200500101A (es) Compuestos de metil-aril o heteroaril-amida sustituida
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
GT200200072A (es) Derivados de dihidro-benzo (b) (1,4)-diazepin-2-ona
GT200400013A (es) Compuestos de pirazolotriazina y usos de los mismos
GT200100160A (es) Derivados 4-fenil-piridina.
GT200400173A (es) Compuestos de aril o heteroaril amida
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
GT200300226A (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos
CL2008003787A1 (es) Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.
BR0311494A (pt) Novos indóis substituìdos
UY27976A1 (es) Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia
GT200300219A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
GT200300045A (es) Nuevos derivados de tiazol como antagonistas del receptor npy
GT200400032A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
GT200200269A (es) Derivados de 7-amino-benzotiazol
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
GT200300033A (es) Derivados de nicotinamida utiles como inhibidores de pde4
GT200600128A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
GT200200280A (es) Lactamas como antagonistas de taquiquininas